Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This is the first multiple-dose experience in humans with MOA-728 in an oral formulation.
This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK)
of MOA-728 following administration of ascending multiple oral doses to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.